Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …

Despite the liver being the primary site for clearance of xenobiotics utilizing a myriad of
mechanisms ranging from cytochrome P450 enzyme pathways, glucuronidation, and biliary …

The Child or Child-Turcotte score (1964) was proposed to assess prognosis in patients with
cirrhosis and portal hypertension as a predictor of postoperative (portocaval shunt surgery) …

Trastuzumab deruxtecan (DS‐8201) is a human epidermal growth factor receptor 2 (HER2)–
targeting antibody–drug conjugate with a novel enzyme‐cleavable linker, a topoisomerase I …

Purpose Berzosertib (formerly M6620) is the first-in-class inhibitor of ataxia–telangiectasia
and Rad3-related protein, a key component of the DNA damage response, and being …

BACKGROUND From a clinical pharmacology perspective, oncology drug development is
associated with unique challenges compared with other therapeutic areas. 1, 2 Clinical …

In recent years, a number of tyrosine kinase inhibitors (TKIs) have been approved for the
treatment of non‑small cell lung cancer. These novel treatments exhibit improved efficacy …

Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI),
undergoes significant hepatic elimination. In this phase 1 study, we assessed the effects of …

Pexidartinib is a kinase inhibitor that induces tumor response and improvements in
symptoms and functional outcomes in adult patients with symptomatic tenosynovial giant cell …

Pexidartinib is a novel oral small‐molecule tyrosine kinase inhibitor targeting the colony‐
stimulating factor 1 receptor. Pexidartinib undergoes extensive hepatic metabolism via …